Lixte Biotech Hldgs (LIXT) 0.2600

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lixte Biotech Hldgs (LIXT) 0.2600 $LIXT

Neurofibromatoses Type II Therapeutics Pipeline Review 2015 - 4 Companies & 6 Drug Profiles
M2 - Thu Jun 25, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9gp7cv/neurofibromatoses) has announced the addition of the "Neurofibromatoses Type II - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neurofibromatoses Type II, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neurofibromatoses Type II and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Arno Therapeutics, Inc. - CalAsia Pharmaceuticals, Inc. - Nexgenix Pharmaceuticals, LLC - Lixte Biotechnology Holdings, Inc. Drug Profiles - AR-42 - FRAX-597 - LB-201 - LB-205 - NXD-30001 - Small Molecules to Inhibit Hsp90 for Neurofibromatosis Type 2 For more information visit http://www.researchandmarkets.com/research/9g...bromatoses

Septic Shock Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Tue Jun 16, 5:31AM CDT
The report "Septic Shock - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Septic Shock. Septic shock is life-threatening low blood pressure (shock) due to sepsis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Septic Shock with 30 market data tables and 14 figures, spread across 77 pages is available at http://www.rnrmarketresearch.com/septic-shock...eport.html .
CGEN: 6.63 (+0.06)

Global Traumatic Brain Injury Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f9f48/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - ALSP, Inc. - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Io Therapeutics, Inc. - Ischemix - Karyopharm Therapeutics, Inc. - Kyorin Pharmaceutical Co., Ltd. - Levolta Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - PharmatrophiX, Inc. - Phylogica Limited - Prevacus, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - RAPID Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - SynZyme Technologies, LLC - Tetra Discovery Partners LLC - vasopharm GmbH - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/9f...atic_brain
NBS: 2.25 (-0.09), LPTN: 0.28 (unch), CNCE: 15.71 (+0.27), ATHX: 1.14 (-0.01), KPTI: 25.57 (+0.24), CUR: 1.69 (-0.01)

Myocardial Ischemia - Pipeline Review, H1 2015 - 8 Companies & 22 Drug Profiles
M2 - Wed Mar 25, 12:05PM CDT
Research and Markets (http://www.researchandmarkets.com/research/sc6lt6/myocardial) has announced the addition of the "Myocardial Ischemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - CoDa Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Miltenyi Biotec GmbH - Nyken BV - Opsona Therapeutics Ltd. - Taxus Cardium Pharmaceuticals Group Inc. - ViroMed Co., Ltd. Drug Profiles - alferminogene tadenovec - AntimiR-199a - EP-80317 - Gene Therapy for Ischemic Heart Failure - Humanin - LB-100 - LB-102 - MG-53 - NYK-1112 - OPN-305 - Peptagon - PMC-6 - Protein for Myocardial Infarction and Critical Limb Ischemia - Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Recombinant Protein to Inhibit CXCL for Cardiovascular and Immunology - Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia - Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Stem Cell Therapy for Cardiovascular Disease - Stem Cell Therapy for Cardiovascular Diseases - VM-202 For more information visit http://www.researchandmarkets.com/research/sc6lt6/myocardial
BAX: 37.61 (+0.59)

Lixte Completes Private Placement Of Convertible Preferred Stock
PR Newswire - Wed Mar 18, 8:04AM CDT
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today that one of its major shareholders has purchased $1,750,000 of Convertible Preferred stock. If fully converted, these shares would convert to 2,187,500 common shares at a per share price of $0.80.

Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
PR Newswire - Fri Jan 23, 8:04AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number of clinical sites where its Phase I trial of Lixte's lead compound, LB--100, is being conducted, has been expanded from 1 to 5 institutions.

Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 4.20 (+0.24), AMGN: 154.10 (+2.79), RGLS: 10.14 (+0.30), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), PVCT: 0.51 (+0.01), CANF: 2.00 (+0.09), DCTH: 0.84 (unch), NVS: 103.22 (+3.20), XLRN: 30.03 (+0.20)

Brain Ischemia - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttpc9j/brain_ischemia) has announced the addition of the "Brain Ischemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Ischemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Brain Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Brain Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Edge - FibroGen - Immune - Lixte Biotechnology Holdings, - Medestea Research & Production - NeuroNascent, - NeurOp - Spectrum - Sylentis - The International Biotechnology Center (IBC) For more information visit http://www.researchandmarkets.com/research/tt...n_ischemia

Lixte Biotech: A Novel Approach to Boost Existing Cancer Therapies
ACCESSWIRE - Tue Nov 18, 10:05AM CST
WHITEFISH, MT / ACCESSWIRE / November 18, 2014 / Cellular signaling is a complex system of communication that governs basic cellular activities and coordinates cell actions. In many cases, errors in cellular information processing are responsible for diseases like cancer, autoimmune disorders, and diabetes. Researchers are attempting to understand these cellular signaling pathways to effectively treat these disorders and accomplish other medical feats.
SGEN: 47.09 (+0.57)

Lixte's LB-100 Selected as One of Informa and Kantar Health's 2014 Top 10 Most Interesting Oncology Projects to Watch
PR Newswire - Thu Nov 06, 9:00AM CST
Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), a clinical-stage public pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer, has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch for its lead compound, LB-100. For more information, see: http://www.iirusa.com/therapeuticareapartners...ingcos.xml

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 163

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 89

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 129

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 120

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Envision and Tai Tam Put 45 MW Wind Bet to Work in Vietnam

Updated Category News Views 25

A wind site averaging 6.5 meters per second can look unremarkable on a map, yet that is precisely where equipment choices start separating serious developers from brochure merchants. Envision Energy and Vietnam's Tai Tam Group are taking that test on with the 45 MW Phuoc Dan wind project in Khanh Hoa Province. The arrangement follows five years of cooperation, but the...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 25

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 144

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 74

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 84

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 147

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading

Top 5 Most Recently Viewed Articles

Surge in Gold Prices Reflects Political and Economic Tensions

Updated Category News Views 283

Gold Prices Reach New Heights Amid Political Turmoil Gold prices have reached unprecedented levels recently, reflecting a surge in safe-haven demand driven by rising political uncertainties in key regions like the U.S. and Japan. As concerns about potential economic instability grow, this precious metal has emerged as a popular choice for investors looking to protect...

Continue Reading
BlackSky Secures Navy Contract to Enhance Satellite Imaging

Updated Category News Views 222

Alright, here’s the scoop: BlackSky Technology Inc. just bagged a major contract with the U.S. Navy, and it’s all about beefing up their Gen-3 imaging satellites. Now, why does this matter? This initiative is a piece of the broader Project Overmatch—a military strategy designed to supercharge the Joint All Domain Command and Control (JADC2) mission. What’s at...

Continue Reading
Discover the Innovative FINGER GRIP for Enhanced Sports Performance

Updated Category News Views 217

Enhancing Sports with the Innovative FINGER GRIP In the dynamic world of sports, having the right equipment can make all the difference. An inventive mind from Pittsburgh has introduced an innovative product, the FINGER GRIP, aimed at elevating performance in games like pickleball and tennis. This new grip is revolutionizing how athletes interact with their paddles and...

Continue Reading
Updated Voting Shares of AB Volvo: Significant Changes

Updated Category News Views 215

Changes in AB Volvo's Voting Shares AB Volvo has recently undergone an important transformation affecting its voting shares. The conversion of 175,000 Series A shares into Series B shares is a key development for the company. This conversion stems from a provision accepted at the 2011 Annual General Meeting, allowing Series A shareholders to switch their shares to Series...

Continue Reading
Warner Bros. Discovery's Q4: Strong Revenue Growth & Future Plans

Updated Category News Views 324

Warner Bros. Discovery Reports Impressive Q4 Results In a recent financial assessment, Warner Bros. Discovery, Inc (NASDAQ: WBD) unveiled its latest quarterly performance, showcasing a fiscal fourth-quarter revenue of $10.03 billion. Although this represented a slight 1% ex-FX decline compared to the previous year, it was just shy of analysts' expectations of $10.19...

Continue Reading